• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ecallantide.

作者信息

Zuraw Bruce, Yasothan Uma, Kirkpatrick Peter

出版信息

Nat Rev Drug Discov. 2010 Mar;9(3):189-90. doi: 10.1038/nrd3125.

DOI:10.1038/nrd3125
PMID:20190785
Abstract
摘要

相似文献

1
Ecallantide.艾卡肽德
Nat Rev Drug Discov. 2010 Mar;9(3):189-90. doi: 10.1038/nrd3125.
2
Hereditary angioedema--therapies old and new.遗传性血管性水肿——新旧疗法
N Engl J Med. 2010 Aug 5;363(6):581-3. doi: 10.1056/NEJMe1006450.
3
Therapeutic agents for hereditary angioedema.遗传性血管性水肿的治疗药物。
N Engl J Med. 2011 Jan 6;364(1):85; author reply 86. doi: 10.1056/NEJMc1010085.
4
Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.遗传性血管性水肿患者血管性水肿发作的触发因素和前驱症状
J Investig Allergol Clin Immunol. 2016;26(6):383-386. doi: 10.18176/jiaci.0102.
5
Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.依卡兰肽治疗急性遗传性血管性水肿发作：按患者特征分析疗效。
Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528.
6
Response time for ecallantide treatment of acute hereditary angioedema attacks.依替巴肽治疗急性遗传性血管性水肿发作的反应时间。
Ann Allergy Asthma Immunol. 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005. Epub 2010 Oct 25.
7
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.依卡兰肽（DX-88）治疗急性遗传性血管性水肿发作：两项双盲、3 期研究的汇总分析。
J Allergy Clin Immunol. 2011 Jul;128(1):153-159.e4. doi: 10.1016/j.jaci.2011.03.006. Epub 2011 Apr 9.
8
Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency.3例获得性C1抑制物缺乏患者对利妥昔单抗治疗的临床和生物学反应
Ann Allergy Asthma Immunol. 2017 Oct;119(4):380-382. doi: 10.1016/j.anai.2017.07.032. Epub 2017 Aug 31.
9
Icatibant.依卡替班
Br J Clin Pharmacol. 2010 May;69(5):425-6. doi: 10.1111/j.1365-2125.2010.03642.x.
10
Current and emerging therapies to prevent hereditary angioedema attacks.目前和新兴的预防遗传性血管性水肿发作的疗法。
Am J Manag Care. 2018 Aug;24(14 Suppl):S299-S307.

引用本文的文献

1
Bat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential.蝙蝠衍生的寡肽 LE6 可抑制接触激肽途径，具有抗血栓炎症和治疗中风的潜力。
Zool Res. 2024 Sep 18;45(5):1001-1012. doi: 10.24272/j.issn.2095-8137.2023.372.
2
Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.人血浆激肽释放酶：在凝血、纤维蛋白溶解、炎症途径及其他方面的作用。
Front Physiol. 2023 Aug 30;14:1188816. doi: 10.3389/fphys.2023.1188816. eCollection 2023.
3
SYNBIP: synthetic binding proteins for research, diagnosis and therapy.

本文引用的文献

1
New treatments addressing the pathophysiology of hereditary angioedema.针对遗传性血管性水肿病理生理学的新疗法。
Clin Mol Allergy. 2008 Apr 14;6:2. doi: 10.1186/1476-7961-6-2.
2
Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.激肽释放酶在遗传性血管性水肿发病机制中的关键作用：新型激肽释放酶抑制剂依库珠单抗的一项临床试验
J Allergy Clin Immunol. 2007 Aug;120(2):416-22. doi: 10.1016/j.jaci.2007.04.028. Epub 2007 Jun 7.
3
Plasma bradykinin in angio-oedema.血管性水肿中的血浆缓激肽。
SYNBIP：用于研究、诊断和治疗的合成结合蛋白。
Nucleic Acids Res. 2022 Jan 7;50(D1):D560-D570. doi: 10.1093/nar/gkab926.
4
Icatibant promotes patients' behavior modification associated with emergency room visits during an acute attack of hereditary angioedema.依卡替班可促进遗传性血管性水肿急性发作期间与急诊就诊相关的患者行为改变。
Intractable Rare Dis Res. 2021 May;10(2):142-145. doi: 10.5582/irdr.2021.01010.
5
Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction.血液透析患者过早衰老的分子机制：固有和适应性免疫功能障碍的复杂相互作用。
Int J Mol Sci. 2020 May 12;21(10):3422. doi: 10.3390/ijms21103422.
6
Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors.通过定向进化人 TFPI1 开发的新型 MASP-2 抑制剂是有效的凝集素途径抑制剂。
J Biol Chem. 2019 May 17;294(20):8227-8237. doi: 10.1074/jbc.RA119.008315. Epub 2019 Apr 5.
7
Phage display-derived human antibodies in clinical development and therapy.临床开发与治疗中基于噬菌体展示技术获得的人源抗体。
MAbs. 2016 Oct;8(7):1177-1194. doi: 10.1080/19420862.2016.1212149. Epub 2016 Jul 14.
8
Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold.嗜极端环境的50S核糖体RNA结合蛋白L35Ae作为构建替代蛋白质支架的基础
PLoS One. 2015 Aug 6;10(8):e0134906. doi: 10.1371/journal.pone.0134906. eCollection 2015.
9
Management of acute attacks of hereditary angioedema: role of ecallantide.遗传性血管性水肿急性发作的管理：依库珠单抗的作用
J Blood Med. 2015 Apr 16;6:115-23. doi: 10.2147/JBM.S66825. eCollection 2015.
10
Unleashing the therapeutic potential of human kallikrein-related serine proteases.释放人激肽释放酶相关丝氨酸蛋白酶的治疗潜力。
Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20.
Lancet. 1998 Jun 6;351(9117):1693-7. doi: 10.1016/S0140-6736(97)09137-X.
4
Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein.获得一组纤溶酶和血浆激肽释放酶的高亲和力、高特异性蛋白抑制剂。
Mol Divers. 1996 Oct;2(1-2):119-24. doi: 10.1007/BF01718709.
5
Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin.利用噬菌体展示技术对高亲和力蛋白酶抑制剂进行迭代优化。2. 血浆激肽释放酶和凝血酶。
Biochemistry. 1996 Jun 18;35(24):8058-67. doi: 10.1021/bi952629y.